DNA Script company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Founded Year



Series C - II | Alive

Total Raised


Last Raised

$35M | 7 mos ago

Mosaic Score

+10 points in the past 30 days

What is a Mosaic Score?
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

About DNA Script

DNA Script is a biotech start-up that manufactures de novo synthetic nucleic acids using an enzymatic technology. The company aims to introduce a biochemical process for DNA and RNA synthesis based on the use of efficient enzymes. This technology mimics the way nature produces genetic code and enables enhanced performance while minimizing the use of harsh chemicals.

DNA Script Headquarter Location

67 avenue de Fontainebleau

Le Kremlin-Bicetre, 94270,


+33 1 56 20 56 00

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing DNA Script

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned DNA Script in 1 CB Insights research brief, most recently on Oct 5, 2021.

Expert Collections containing DNA Script

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

DNA Script is included in 3 Expert Collections, including Synthetic Biology.


Synthetic Biology

238 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

DNA Script Patents

DNA Script has filed 18 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • DNA
  • Biotechnology
patents chart

Application Date

Grant Date


Related Topics




Molecular biology, DNA replication, DNA, Genetics, Biotechnology


Application Date


Grant Date



Related Topics

Molecular biology, DNA replication, DNA, Genetics, Biotechnology



Latest DNA Script News

French Defense Innovation Agency Investigates the Use of DNA Script’s SYNTAX System to Synthesize Custom qPCR Probes for On-demand Detection of Biothreats

Jun 28, 2022

In response to strong results, the Agency has extended DNA Script’s contract June 28, 2022 06:00 AM Eastern Daylight Time SOUTH SAN FRANCISCO, Calif. & PARIS--( BUSINESS WIRE )--DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, has announced the first successful qPCR assays using primers and probes synthesized by a customer via enzymatic synthesis using the company’s SYNTAX System DNA printer. This success was achieved as part of a contract with the French Defense Innovation Agency, in liaison with the French Armament General Directorate (DGA), first announced in January 2021. The partnership leverages the SYNTAX System to produce high-quality DNA primers and probes to rapidly develop qPCR assays for infectious disease detection. Based on these results, the collaboration has been extended to further test EDS primers and probes for qPCR assay development, giving the DGA access to new versions of synthesis and labeling technologies that the company commercially develops. This market’s applications in biodefense are a strategic focus contributing to the sovereign production of biological assays for the French Ministry for the Armed Forces. “This extension validates the importance of our SYNTAX benchtop DNA printing system for rapid response programs,” said Thomas Ybert, CEO and co-founder of DNA Script. “We have demonstrated that SYNTAX can consistently print high-quality DNA probes for mobile and onsite deployment, enabling same-day qPCR from design to results, which is an enormous advantage for any pathogen early warning system.” The ultimate goal is to create a platform that can quickly develop new assays targeting biological threats or emerging pathogens during an outbreak’s earliest phases. “COVID has taught us that we need to be prepared for new threats,” said Ybert. “Our work with the DGA takes that preparation to the next level, providing the ability to respond faster to new biothreats.” The SYNTAX System delivers a DNA printing technology that is compliant with the DGA’s requirements. The system relies on enzymatic synthesis, a safer, more sustainable technology that does not rely on toxic reagents or produce the hazardous organic waste associated with phosphoramidite chemistry DNA printing. The SYNTAX printer synthesizes high-quality, custom nucleic acids for immediate use within hours. As a result, researchers developing new assays can save days, sometimes even weeks, by printing in-house versus waiting for oligos to be delivered from third-party service providers. This capability is critically important for programs focused on improving the response time to emerging biological risks and biothreats. Financial terms were not disclosed. About DNA Script Founded in 2014, DNA Script is a pioneering life sciences technology company developing a new, faster, more powerful and versatile way to design and manufacture nucleic acids. The company has developed an alternative to traditional DNA synthesis called Enzymatic DNA Synthesis, or EDS, enabling this technology to be accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX System. By putting DNA synthesis back in the lab, DNA Script aims to transform life sciences research through innovative technology that gives researchers unprecedented control and autonomy. www.dnascript.com Contacts

DNA Script Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

DNA Script Rank

  • When was DNA Script founded?

    DNA Script was founded in 2014.

  • Where is DNA Script's headquarters?

    DNA Script's headquarters is located at 67 avenue de Fontainebleau, Le Kremlin-Bicetre.

  • What is DNA Script's latest funding round?

    DNA Script's latest funding round is Series C - II.

  • How much did DNA Script raise?

    DNA Script raised a total of $335.04M.

  • Who are the investors of DNA Script?

    Investors of DNA Script include Baillie Gifford & Co., Irving Investors, T. Rowe Price, Sino Biopharmaceutical, eureKARE and 26 more.

  • Who are DNA Script's competitors?

    Competitors of DNA Script include Catalog Technologies.

You May Also Like

Kilobaser Logo

KioBaser is building what it dubs "Nespresso machine of DNA synthesis". The machine creates DNA primers, a short single strand of RNA or DNA (generally about 18-22 bases) that serves as a starting point for DNA synthesis.

Evonetix Logo

Evonetix develops a desktop, short-latency solution to synthesize DNA to facilitate the field of synthetic biology, with application across industries including healthcare, pharma, biotech, food and agriculture and data storage.

Molecular Assemblies Logo
Molecular Assemblies

Molecular Assemblies develops an enzymatic DNA synthesis technology designed to power DNA-based products. Enzymatic DNA synthesis can write long, pure DNA, which is required to free the potential of synthetic biology applications, such as personalized medicines (including CAR-T cell therapies and CRISPR gene editing) and advanced agricultural and industrial products, through gene development and DNA-based data storage.

Helixworks Technologies

Helixworks Technologies is a biotechnology company specializing in DNA synthesis.


Iridia is developing a DNA-based data storage solution. By combining DNA polymer synthesis technology, electronic nano-switches and semiconductor fabrication technologies, Iridia is developing a highly-parallel format to enable an array of nanomodules with the potential to store data at exceptionally high density.


Developer of instrumentation for gene synthesis analysis. The company develops a DNA and RNA synthesizer for molecular biology research purposes. The platform aims to deliver less expensive, higher quality, reduced turn-around-time oligonucleotide synthesis solutions.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.